InMed Pharmaceuticals Inc (INM) has a current Price-to-Book (P/B) ratio of 0.38. Compared to its 3-year average P/B ratio of 0.30, the current P/B ratio is approximately 25.42% higher. Relative to its 5-year average P/B ratio of 0.73, the current P/B ratio is about -47.39% higher. InMed Pharmaceuticals Inc (INM) has a Forward Free Cash Flow (FCF) yield of approximately -170.41%. Compared to its 3-year average FCF yield of -260.49%, the current FCF yield is approximately -34.58% lower. Relative to its 5-year average FCF yield of -221.31%, the current FCF yield is about -23.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for INM competitors is 0.06, providing a benchmark for relative valuation. InMed Pharmaceuticals Inc Corp (INM.O) exhibits a P/S ratio of 0.16, which is 171.42% above the industry average. Given its robust revenue growth of -26.22%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of INM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of INM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is INM currently overvalued or undervalued?

What is InMed Pharmaceuticals Inc (INM) fair value?

INM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of InMed Pharmaceuticals Inc (INM) is between 0.61 to 2.79 according to relative valuation method.

How does INM's valuation metrics compare to the industry average?

The average P/S ratio for INM's competitors is 0.06, providing a benchmark for relative valuation. InMed Pharmaceuticals Inc Corp (INM) exhibits a P/S ratio of 0.16, which is 171.42% above the industry average. Given its robust revenue growth of -26.22%, this premium appears unsustainable.

What is the current P/B ratio for InMed Pharmaceuticals Inc (INM) as of Mar 03 2026?

As of Mar 03 2026, InMed Pharmaceuticals Inc (INM) has a P/B ratio of 0.38. This indicates that the market values INM at 0.38 times its book value.

What is the current FCF Yield for InMed Pharmaceuticals Inc (INM) as of Mar 03 2026?

As of Mar 03 2026, InMed Pharmaceuticals Inc (INM) has a FCF Yield of -170.41%. This means that for every dollar of InMed Pharmaceuticals Inc's market capitalization, the company generates -170.41 cents in free cash flow.

What is the current Forward P/E ratio for InMed Pharmaceuticals Inc (INM) as of Mar 03 2026?

As of Mar 03 2026, InMed Pharmaceuticals Inc (INM) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of InMed Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for InMed Pharmaceuticals Inc (INM) as of Mar 03 2026?

As of Mar 03 2026, InMed Pharmaceuticals Inc (INM) has a Forward P/S ratio of 0.16. This means the market is valuing INM at $0.16 for every dollar of expected revenue over the next 12 months.

INM Valuation